Core Viewpoint - Aohua Endoscopy (688212.SH) reported a significant decline in financial performance for the first three quarters of 2025, with a notable drop in revenue and net profit compared to the previous year [1]. Financial Performance Summary - For the period of January to September 2025, the company achieved operating revenue of 422.63 million yuan, a year-on-year decrease of 15.57% [1][3]. - The net profit attributable to shareholders was -56.09 million yuan, compared to a profit of 37.30 million yuan in the same period last year [1][3]. - The net profit after deducting non-recurring gains and losses was -68.10 million yuan, down from a profit of 1.48 million yuan in the previous year [1][3]. - The net cash flow from operating activities was -98.69 million yuan, worsening from -138 million yuan year-on-year [1][3]. Previous Financial Year Comparison - In 2024, Aohua Endoscopy reported total operating revenue of 750 million yuan, reflecting a year-on-year growth of 10.54% [4]. - The net profit attributable to shareholders for 2024 was 21.01 million yuan, which represented a decline of 63.68% compared to the previous year [4]. - The net profit after excluding non-recurring items was -628.62 million yuan, down from 4.45 million yuan in the previous year [4].

Group 1: Medical Device Sector - The medical device sector is expected to benefit from policies promoting large-scale equipment updates and innovative devices, with a focus on domestic equipment replacement and bidding recovery [1] - The high-end medical equipment industry is projected to maintain high prosperity by 2025, with strong cost-performance ratios due to significant sector corrections from 2021 to 2024 [1] - Recommended stocks in the medical device sector include Mindray Medical (300760), United Imaging, Haitai New Light, and others, with a focus on segments like hemodialysis, ultrasound, endoscopy, and oral care [1] Group 2: Medical Consumption Sector - The government has introduced multiple policies to enhance grassroots medical service capabilities, aiming for improved accessibility to medical services by 2027 [2] - With the enhancement of medical insurance payments and increased public payment capacity, the medical consumption sector is expected to have significant growth potential [2] - Recommended stocks in the medical consumption sector include Gushengtang, with additional attention on Yingkang Life (300143) and Ruil Group [2] Group 3: Offline Pharmacy Sector - The offline pharmacy sector is currently experiencing low valuations due to a weak macroeconomic environment, with a significant number of pharmacies closing down, leading to increased market concentration [3] - National policies are supporting the diversified development of pharmacies, with leading pharmacies adapting their store formats and focusing on non-pharmaceutical products to drive growth [3] - Recommended stocks in the offline pharmacy sector include Yifeng Pharmacy (603939) and Daclin (603233), with additional focus on Laobaixing, Yixin Hall (002727), and others [3]

智通财经APP获悉，东方财富证券发布研报称，随着中国创新药License-out项目总金额创下新纪录，临 床前项目占比持续保持高位，ADC、双/多抗、小核酸等新兴疗法，以及代谢领域中肥胖适应症等或为 未来License-out项目的重点方向。我国创新药企业已从高投入低产出的研发探索期过渡到了管线密集收 获期，与此同时商保的发展有望让原先的创新药"单一"支付向多元支付转型。此外，医疗器械2025年招 采端持续复苏，关注设备更新政策与资金落地持续驱动需求释放。 东方财富证券主要观点如下： 标的方面 创新药板块建议关注百济神州(06160)、恒瑞医药(01276)、中国生物制药(01177)、三生制药(01530)/三生 国健(688336.SH)、石药集团(01093)等。医疗器械板块：1）内需修复：建议关注迈瑞医疗(300760.SZ)、 联影医疗(688271.SH)、开立医疗(300633.SZ)、澳华内镜(688212.SH)等；2）出海兑现：建议关注海泰新 光(688677.SH)、新产业(300832.SZ)等；3）脑机接口：建议关注诚益通(300430.SZ)、伟思医疗 (688580.SH)等。 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" [2]. Core Viewpoints - The recent performance of the pharmaceutical sector has been sluggish, with the innovative drug sector experiencing a significant rise in expectations earlier this year, now undergoing a correction. However, innovative medical devices are expected to benefit from ongoing government support for medical equipment upgrades and accelerated domestic replacement of high-end medical devices, alongside continuous expansion into overseas markets. A recovery is anticipated starting in Q3 2025, with performance gradually improving in 2026 [3][9]. - The high-end medical device sector is driven by the recovery of in-hospital procurement, suggesting a focus on companies such as United Imaging, Shandong Weigao, and Mindray Medical. The demand for consumer medical devices is gradually recovering, with a shift in market share from imported brands, indicating potential in companies like Kefu Medical and Yuyue Medical. The orthopedic consumables market has reached a price floor, with opportunities for market share growth in orthopedic robotics and overseas expansion, highlighting companies like Aikang Medical and Chuangli Medical [3][9]. - The pharmaceutical equipment sector is undergoing a cyclical recovery, with rapid overseas growth opening new avenues for growth. Domestic margins are expected to stabilize and profitability to improve, with a return to rational competition anticipated from late 2024. The recovery in innovative drug financing and frequent business development transactions are expected to drive a revival in contract manufacturing organizations (CMOs), positively impacting the pharmaceutical equipment industry. Additionally, global strategic safety backups and commitments from multinational pharmaceutical companies to invest in the U.S. market are projected to accelerate fixed asset expenditures in the pharmaceutical sector over the next three years, with a focus on companies like Senson International and Dongfulong [3][9]. - In the CXO and upstream life sciences supply chain, leading global CXO companies such as WuXi AppTec and Kanglong Huacheng are highlighted. Domestic clinical CRO leaders like Tigermed and Pruce are also recommended, along with resource-based CXOs such as Zhaoyan New Drug and Mediso. The upstream life sciences supply chain includes companies like Baipusais and Haier Biomedical [3][9]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's return was -1.04% last week, ranking 17th among 31 sub-industry indices. The medical services sub-sector had the highest weekly return at 1.67%, while the pharmaceutical commercial sub-sector had a return of -4.26% [3][9]. Industry Trends - The report emphasizes the ongoing low performance of the pharmaceutical sector, particularly in innovative drugs, while highlighting the potential recovery in innovative medical devices and the pharmaceutical equipment sector [3][9]. Recommendations - Specific companies to watch include United Imaging, Mindray Medical, Kefu Medical, and Aikang Medical in the high-end medical device sector, as well as Senson International and WuXi AppTec in the pharmaceutical equipment and CXO sectors [3][9].

（编辑 任世碧） 证券日报网讯 12月12日晚间，澳华内镜发布公告称，公司于2025年12月12日召开第三届董事会第一次 会议，全体董事一致同意选举顾小舟先生担任公司董事长，任期自公司第三届董事会第一次会议审议通 过之日起至第三届董事会届满之日止。公司于2025年12月12日召开第三届董事会第一次会议，审议通过 了《关于聘任公司高级管理人员的议案》，同意聘任顾小舟先生担任公司总经理；同意聘任钱丞浩先 生、施晓江先生、包寒晶先生、刘力攀女士担任公司副总经理；同意聘任施晓江先生担任公司董事会秘 书；同意聘任钱丞浩先生担任公司财务负责人。2025年12月12日，公司召开第三届董事会第一次会议， 审议通过了《关于聘任公司证券事务代表的议案》，同意聘任万梦琪女士为公司证券事务代表。 ...

Investment Rating - Industry investment rating is "Outperform" compared to the market, expecting the industry index to perform better than the CSI 300 index by more than 5% in the next six months [22]. Core Insights - The medical device bidding environment remains robust, with a significant trend towards high-end products. Since 2025, the release of equipment update policy dividends has led to sustained market demand growth, keeping bidding activities at a high level. Monthly procurement scales from July to November 2025 were 13.4 billion, 14.6 billion, 16.4 billion, 16.4 billion, and 20.9 billion respectively, with year-on-year growth rates of +24%, +31%, +2%, +14%, and +0% [3][11]. - The bidding environment is benefiting leading companies in the industry, with procurement scales for ultrasound, CT, MRI, DR, DSA, and gastrointestinal endoscopes showing significant year-on-year growth in November 2025 [4][12][14]. - The report emphasizes the importance of high-end and intelligent medical devices, suggesting that leading domestic companies like Mindray, United Imaging, Kaili Medical, and Aohua Endoscopy should be closely monitored for their strategic positioning in the market [5][20]. Summary by Sections Market Trends - The medical device market is experiencing a strong revival, with a notable focus on high-end imaging equipment such as CT, MRI, and ultrasound, which together account for nearly 62% of the total bidding amount [3][11]. - In November 2025, the procurement scale for ultrasound was 2.301 billion (yoy +17%), CT was 2.605 billion (yoy +26%), MRI was 2.394 billion (yoy +6%), DR was 460 million (yoy +50%), and DSA was 1.016 billion (yoy +4%) [12][14]. Company Performance - Domestic companies are aligning with industry trends, with Mindray achieving 1.318 billion (yoy +12%), United Imaging at 1.433 billion (yoy +30%), Kaili Medical at 247 million (yoy +62%), and Aohua at 109 million (yoy +60%) in November 2025 [17]. Investment Recommendations - The report recommends focusing on domestic leading enterprises that are enhancing their high-end and intelligent product offerings, as the bidding environment is expected to remain favorable due to ongoing policy support for equipment updates [5][20].

SHANGHA 8 Yin Chena Road Mi anahai 200120 P R China 上海市通力律师事务所关于上海澳华内镜股份有限公司 2025 年第四次临时股东大会的法律意见书 致:上海澳华内镜股份有限公司 上海市通力律师事务所(以下简称"本所")接受上海澳华内镜股份有限公司(以 下简称"公司")的委托,指派本所茹秋乐律师、赵伯晓律师(以下简称"本所律师") 根据《中华人民共和国公司法》《中华人民共和国证券法》等法律法规和规范性文件(以 下统称"法律法规")及《上海澳华内镜股份有限公司章程》(以下简称"公司章程") 的规定就公司 2025 年第四次临时股东大会(以下简称"本次股东大会")相关事宜出 具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以 了核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中 的所有签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、 完整和有效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股东大会 人员资格和召集 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-079 上海澳华内镜股份有限公司 特此公告。 上海澳华内镜股份有限公司董事会 2025年12月13日 附件：职工代表董事简历 陈鹏，男，1984 年 5 月出生，中国国籍，无境外永久居留权。毕业于北京 大学，获硕士学位。2009 年 9 月至 2011 年 7 月，任北京大学工学院科研项目 工程师；2011 年 8 月至 2015 年 1 月，任公司技术开发部经理、质量部经理。 2015 年 1 月至 2025 年 12 月，任公司副总经理。2024 年 11 月至 2025 年 12 月， 任公司董事。2025 年 12 月至今，任公司职工代表董事。 截至本公告披露日，陈鹏先生直接持有公司股份 3.13 万股，通过上海小洲 光电科技有限公司间接持有公司股份约 18.79 万股。陈鹏先生与公司控股股东、 实际控制人、持有公司 5%以上股份的股东及公司其他董事、高级管理人员之间 不存在关联关系，也不存在受到中国证券监督管理委员会及其他有关部门处罚 或证券交易所惩戒的情形，亦不存在因涉嫌犯罪被司法机关立案侦查或涉嫌违 法违规被中国证券监督管理委员会立 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-078 上海澳华内镜股份有限公司 公司于 2025 年 12 月 12 日召开第三届董事会第一次会议，全体董事一致同 意选举顾小舟先生担任公司董事长，任期自公司第三届董事会第一次会议审议 通过之日起至第三届董事会届满之日止。 同日选举产生了公司第三届董事会审计委员会、提名委员会、薪酬与考核 委员会、战略委员会委员及主任委员（召集人），各专门委员会组成如下： | 序号 | 专门委员会名称 | 主任委员（召集人） | 委员 | | --- | --- | --- | --- | | 1 | 审计委员会 | 董慧 | 董慧、孔非凡、陈鹏 | | 2 | 提名委员会 | 赵俊 | 赵俊、陈宥攸、顾小舟 | | 3 | 薪酬与考核委员会 | 董慧 | 董慧、孔非凡、钱丞浩 | | 4 | 战略委员会 | 顾小舟 | 顾小舟、陈鹏、赵俊 | 关于董事会完成换届选举、变更法定代表人及聘任高 级管理人员、证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-077 上海澳华内镜股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一） 股东大会召开的时间：2025 年 12 月 12 日 （二） 股东大会召开的地点：上海市闵行区光中路 133 弄 66 号澳华内镜大厦十 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 203 | | --- | --- | | 普通股股东人数 | 203 | | 2、出席会议的股东所持有的表决权数量 | 75,615,431 | | 普通股股东所持有表决权数量 | 75,615,431 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 57.2125 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 57.21 ...